Out of 279 consecutive patients with advanced NSCLC who initially received PD‐1/PD‐L1 inhibitor therapy between March 2016 to February 2018, 156 were finally enrolled in this study (Figure 1). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.